Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Acelrx Pharmaceutica (ACRX)

Acelrx Pharmaceutica (ACRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Acelrx Pharmaceutica 25821 INDUSTRIAL BOULEVARD SUITE 400 HAYWARD CA 94545 USA

P: 650-216-3500 F: 650-216-6500

Description:

AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician's office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California.

Key Statistics

Overview:

Market Capitalization, $K 121,564
Shares Outstanding, K 119,180
Annual Sales, $ 5,420 K
Annual Net Income, $ -40,380 K
Last Quarter Sales, $ 440 K
Last Quarter Net Income, $ -9,840 K
60-Month Beta 0.82
% of Insider Shareholders 7.50%
% of Institutional Shareholders 20.77%
Float, K 110,242
% Float 92.50%

Growth:

1-Year Return -25.55%
3-Year Return -74.18%
5-Year Return -72.28%
5-Year Revenue Growth -71.86%
5-Year Earnings Growth 21.67%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 08/16/21
Earnings Per Share ttm -0.36
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year 0.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ACRX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -3.99
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -48.97%
Profit Margin % -745.02
Net Margin % N/A
Debt/Equity N/A
Price/Sales 22.45
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.30
Interest Coverage 0.00
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar